Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.54 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.52 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.52 |
| ▸ | CALCR | P30988 | 4/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11997748 | 1.00 | KEAP1 (0.56) | KEAP1SLC6A2OPRM1OPRD1CALCRL | |
| SCHEMBL30163250 | 1.00 | KEAP1 (0.56) | KEAP1SLC6A2OPRM1OPRD1CALCRL | |
| SCHEMBL15130591 | 0.97 | OPRM1 (0.55) | KEAP1SLC6A2OPRM1OPRD1CALCR | |
| SCHEMBL28210612 | 0.97 | OPRM1 (0.55) | KEAP1SLC6A2OPRM1OPRD1CALCR | |
| SCHEMBL30163263 | 0.97 | OPRM1 (0.55) | KEAP1SLC6A2OPRM1OPRD1CALCR | |
| SCHEMBL14549930 | 0.97 | OPRM1 (0.55) | KEAP1SLC6A2OPRM1OPRD1CALCR | |
| SCHEMBL28846618 | 0.97 | OPRM1 (0.55) | KEAP1SLC6A2OPRM1OPRD1CALCR | |
| SCHEMBL30163405 | 0.96 | OPRM1 (0.56) | KEAP1SLC6A2OPRM1OPRD1CALCR | |
| SCHEMBL30163248 | 0.95 | OPRM1 (0.55) | KEAP1SLC6A2OPRM1OPRD1CALCR | |
| SCHEMBL29597272 | 0.94 | OPRM1 (0.55) | KEAP1SLC6A2OPRM1OPRD1CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012454-A1 | Orally Disintegrating Compositions of Linaclotide | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012454-A1 | Orally Disintegrating Compositions of Linaclotide | LPXN, SI, CEL | KEAP1 3847/4885SLC6A2 2887/4885OPRM1 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.